When the SUSTAIN and STEP trial data started rolling in, researchers found something that made a lot of physicians pause. In the STEP 1 trial published in the New England Journal of Medicine, participants who took semaglutide for 68 weeks lost an average of 14.9% of their body weight — a result that rivaled bariatric surgery outcomes. But the follow-up data told an equally important story: when participants stopped the drug, they regained roughly two-thirds of the weight within a year. That finding, more than anything else, has reshaped the conversation around one of the most common questions men ask before starting a GLP-1 medication — how long do I actually need to take this?
The answer is more nuanced than most people expect, and it touches on fundamental questions about obesity as a disease, metabolic adaptation, and what sustainable health actually looks like. Whether you are currently on semaglutide, considering it, or simply curious about the science, understanding the duration question helps clarify what this medication can and cannot do for your long-term metabolic health.
What the Clinical Trials Tell Us About Long-Term Use
Semaglutide is a GLP-1 receptor agonist, meaning it mimics the action of a naturally occurring gut hormone that regulates appetite, insulin secretion, and gastric emptying. It was originally approved for type 2 diabetes management under the brand name Ozempic, and later approved at a higher dose (2.4 mg weekly) for chronic weight management under the name Wegovy. That word — chronic — is doing a lot of work in the FDA’s framing of this drug.
The longest continuous trial data we have comes from the STEP 5 trial, which followed participants for 104 weeks — two full years. Participants maintained an average weight loss of 15.2% over that period, with continued metabolic improvements including reductions in waist circumference, blood pressure, and fasting glucose. Critically, weight loss did not plateau into irrelevance — participants were still seeing benefit at the two-year mark. This suggests that for many men, the therapeutic window is not a sprint but a marathon.
The cardiovascular data adds even more urgency to the long-term case. The SELECT trial, published in the New England Journal of Medicine in 2023, followed over 17,000 overweight or obese adults with established cardiovascular disease for a median of 34 months — nearly three years. Semaglutide reduced the risk of major adverse cardiovascular events by 20% compared to placebo. These were not surrogate endpoints. These were real reductions in heart attacks and cardiovascular deaths. You do not generate that kind of outcome in eight weeks.
So from a purely clinical standpoint, the evidence supports long-term use — potentially indefinitely — for men who meet the criteria for treatment and continue to benefit metabolically. The American Diabetes Association and the Obesity Medicine Association both characterize obesity as a chronic disease requiring chronic management, much like hypertension or hyperlipidemia. Stopping the medication without a clear lifestyle infrastructure in place is, biologically speaking, a bit like stopping your blood pressure medication because your numbers look good.
The Weight Regain Problem and What It Means Practically
The rebound data is where things get uncomfortable, and it deserves an honest look. The STEP 4 trial specifically examined what happens when semaglutide is withdrawn after 20 weeks of treatment. Participants who switched to placebo regained most of the weight over the following 48 weeks, while those who continued the drug maintained their losses. This is not a character flaw or a willpower failure — it reflects the biological reality that the hormonal and neurological drivers of appetite and fat storage reassert themselves once the GLP-1 agonism is removed.
What this means practically is that men who want to discontinue semaglutide need to treat the medication period as an investment window, not a cure. The drug buys you time and physiological space to rebuild habits, body composition, and metabolic health. If you use that window to build a meaningful training base, improve your diet quality, address sleep and stress, and — critically — preserve or build muscle mass through resistance training, you are changing the metabolic landscape you return to when you eventually stop. If you use the window to eat slightly less of the same food and do little else, the rebound is far more likely to be severe.
Muscle mass deserves special attention here. Research has shown that GLP-1-driven weight loss can result in meaningful lean mass loss alongside fat loss, particularly in men who are not resistance training and not consuming adequate protein. Since muscle is your primary metabolic engine — influencing insulin sensitivity, resting energy expenditure, and glucose disposal — losing it during a medically supervised weight loss program can undermine the very outcomes you are trying to achieve. This is why any conversation about how long to take semaglutide has to include a parallel conversation about what you are doing in the gym and on your plate.
A practical target for protein during active semaglutide use is 1.6 to 2.2 grams per kilogram of body weight per day, a range supported by meta-analytic data on protein and lean mass preservation during caloric restriction. Pair that with progressive resistance training at least three days per week, and you are meaningfully stacking the deck in your favor — both during treatment and after.
How to Think About Stopping, Cycling, or Continuing
There is no universal answer to how long any individual should take semaglutide, and anyone who gives you a clean timeline without knowing your metabolic history, body composition, cardiovascular risk, and lifestyle infrastructure is simplifying a complex equation. What the evidence does support is a tiered framework for thinking about it.
Men with type 2 diabetes, prediabetes, or established cardiovascular disease have the strongest case for long-term or indefinite use, given the outcomes data from the SELECT trial and the disease-modifying potential at the metabolic level. For men using semaglutide purely for weight management who are otherwise metabolically healthy, the decision to continue, reduce the dose, or eventually taper off should be made in partnership with a physician and ideally after achieving a stable weight supported by a solid training and nutrition foundation.
Some clinicians are experimenting with dose reduction strategies rather than abrupt discontinuation — gradually stepping down the weekly dose to see if a lower maintenance dose sustains outcomes with fewer side effects and lower cost. This approach is not yet well-studied in large trials, but it is physiologically sensible and worth discussing with your prescriber.
What is clear from the research is that this is not a six-week intervention. The men who get the most from semaglutide — in terms of both weight loss and metabolic improvement — are the ones who treat it as a long-term commitment, use the physiological advantages it provides to build real lifestyle changes, and make evidence-based decisions about duration with their physician rather than stopping arbitrarily when they hit a target weight.
The Takeaway
Semaglutide is one of the more powerful metabolic tools available right now, but it is not magic and it is not designed for a short course. The clinical evidence supports long-term use for the right candidates, and the rebound data makes a strong argument that stopping early — without the lifestyle infrastructure to support your new metabolic state — is one of the costlier decisions you can make. Use the medication as the investment window it is. Build muscle, eat enough protein, fix your sleep, and work with your doctor on a duration and exit strategy that reflects your actual health picture. The drug can open the door. What you do once you walk through it is still up to you.